Jane Street’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$19.9M Sell
108,700
-242,700
-69% -$44.7M ﹤0.01% 1788
2025
Q4
$61.8M Sell
351,400
-32,100
-8% -$5.24M 0.01% 817
2025
Q3
$53.7M Buy
383,500
+71,000
+23% +$9.6M 0.01% 919
2025
Q2
$39.2M Buy
312,500
+139,500
+81% +$17.4M 0.01% 936
2025
Q1
$23.7M Buy
173,000
+24,100
+16% +$3.45M 0.01% 1171
2024
Q4
$22.8M Buy
148,900
+74,400
+100% +$12.5M ﹤0.01% 1167
2024
Q3
$14.4M Sell
74,500
-77,800
-51% -$16.3M ﹤0.01% 1543
2024
Q2
$35.3M Buy
152,300
+78,900
+107% +$17.1M 0.01% 887
2024
Q1
$15.8M Sell
73,400
-46,000
-39% -$10.8M ﹤0.01% 1385
2023
Q4
$30.9M Buy
119,400
+5,200
+5% +$1.28M 0.01% 947
2023
Q3
$29.4M Buy
114,200
+39,000
+52% +$10.4M 0.01% 821
2023
Q2
$21.4M Sell
75,200
-34,100
-31% -$10.2M 0.01% 1146
2023
Q1
$30.4M Sell
109,300
-117,200
-52% -$32.4M 0.01% 745
2022
Q4
$62.7M Sell
226,500
-217,400
-49% -$61.4M 0.03% 438
2022
Q3
$119M Buy
443,900
+130,500
+42% +$27.7M 0.05% 234
2022
Q2
$63.9M Buy
313,400
+72,900
+30% +$14.9M 0.03% 446
2022
Q1
$50.6M Sell
240,500
-77,100
-24% -$16.8M 0.02% 680
2021
Q4
$76.2M Sell
317,600
-160,900
-34% -$41.4M 0.03% 470
2021
Q3
$135M Sell
478,500
-173,900
-27% -$57M 0.05% 266
2021
Q2
$226M Buy
652,400
+343,400
+111% +$104M 0.09% 144
2021
Q1
$86.4M Buy
309,000
+37,900
+14% +$10.2M 0.04% 315
2020
Q4
$66.4M Sell
271,100
-2,100
-0.8% -$542K 0.03% 361
2020
Q3
$77.5M Buy
273,200
+35,700
+15% +$9.96M 0.05% 275
2020
Q2
$63.5M Buy
237,500
+84,400
+55% +$25.4M 0.05% 278
2020
Q1
$48.4M Buy
153,100
+93,200
+156% +$28.3M 0.05% 250
2019
Q4
$17.8M Sell
59,900
-27,000
-31% -$7.49M 0.02% 419
2019
Q3
$20.2M Buy
86,900
+9,900
+13% +$2.31M 0.03% 355
2019
Q2
$18M Sell
77,000
-98,700
-56% -$22.8M 0.03% 402
2019
Q1
$41.5M Buy
175,700
+143,400
+444% +$45.2M 0.07% 220
2018
Q4
$9.72M Buy
32,300
+2,800
+9% +$894K 0.02% 595
2018
Q3
$10.4M Sell
29,500
-2,800
-9% -$964K 0.02% 585
2018
Q2
$9.38M Sell
32,300
-20,300
-39% -$5.71M 0.02% 644
2018
Q1
$14.4M Buy
52,600
+24,200
+85% +$7.51M 0.04% 408
2017
Q4
$9.05M Sell
28,400
-34,300
-55% -$11M 0.03% 550
2017
Q3
$19.6M Sell
62,700
-84,400
-57% -$25M 0.06% 279
2017
Q2
$39.9M Buy
147,100
+103,600
+238% +$27.4M 0.14% 138
2017
Q1
$11.9M Sell
43,500
-35,300
-45% -$9.98M 0.05% 324
2016
Q4
$22.3M Buy
78,800
+22,400
+40% +$6.64M 0.1% 170
2016
Q3
$17.7M Buy
56,400
+17,300
+44% +$5.12M 0.08% 201
2016
Q2
$9.46M Buy
39,100
+1,300
+3% +$343K 0.05% 358
2016
Q1
$9.84M Sell
37,800
-16,600
-31% -$4.38M 0.06% 303
2015
Q4
$16.7M Buy
54,400
+18,900
+53% +$5.43M 0.1% 178
2015
Q3
$10.4M Buy
35,500
+7,600
+27% +$2.51M 0.06% 253
2015
Q2
$11.3M Buy
27,900
+21,400
+329% +$8.59M 0.07% 210
2015
Q1
$2.75M Buy
6,500
+5,300
+442% +$2.09M 0.02% 676
2014
Q4
$407K Buy
1,200
+500
+71% +$162K ﹤0.01% 1652
2014
Q3
$232K Buy
+700
New +$231K ﹤0.01% 2087

Other funds holding BIIB

Jane Street's BIIB Position: Q1 2026 in Review

Jane Street reduced its Biogen (BIIB) stake by 56% in Q1 2026, selling an estimated $2.41M and leaving 10,469 shares worth $1.92M. The position accounts for ﹤0.01% of the portfolio, ranked #5178.

Jane Street first reported a position in BIIB in Q2 2013 and has held it in 50 quarters since. The position peaked at $81.3M in Q3 2022. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Jane Street held 10,469 shares of Biogen worth $1.92M as of Q1 2026.
  • Jane Street sold 13,070 Biogen shares in Q1 2026, an estimated $2.41M.
  • Biogen made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #5178 holding.
  • Jane Street first reported a position in Biogen in Q2 2013 and has held it in 50 quarters since.
  • Jane Street's Biogen position peaked at $81.3M in Q3 2022.
  • 1,003 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.